Immunosuppressors of microbial origin

Antibiotiki i Khimioterapiya

Volumn 48, Issue 5, 2003, Pages 25-32

  Bibikova, M V ^a,b   Grammatikova, N E ^a,b   Sazykin, Yu O ^a,b   Katlinsky, A V ^a,b  

^a National Research Centre of Antibiotics   (Russian Federation)

^b I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ANIMAL; CHEMISTRY; FUNGUS; HUMAN; ISOLATION AND PURIFICATION; REVIEW; STREPTOMYCES; SYNTHESIS;

ANIMALS; FUNGI; HUMANS; IMMUNOSUPPRESSIVE AGENTS; STREPTOMYCES;

EID: 0642307959     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Dreyfuss M., Haerry E., Hoffman H. Cyclosporin A and C, new metabolite from Trichoderma polysporum. Rifai. Eur J Appl Microb 1976; 3: 125-133.
2. Takahashi N., Hayano T., Suzuki M. Peptidil-prolyl cis trans isomerase is the cyclosporine A binding protein cyclophilin. Nature 1989; 337: 473-475.
3. Berriman M., Fairlamb A. H. Detail characterization of a cyclophilin from the human malaria parasite Plasmodium falciparum. Biochem J 1998; 334: 2: 437-445.
4. Russian source
5. Dreyfuss M. M., Chapela J. H. Potential of fungi in the discovery of novel, low-molecular weight pharmaceuticals. The discovery of natural products with therapeutic potential. Gullo V. P., ed. London; 1994; 49-80.
6. Kino T., Hatanaka M., Hashimoto M. et al. FK-506, a novel immuno-suppressant isolated from Streptomyces. I. Fermentation, isolation and physicochemical, biological, and biochemical characteristics. J Antibiotics 1987; 40: 1249-1255.
7. Damont F. J., Byrne K. M., Sigal N. H. et al. Novel immunosuppressive agents. Eur Pat 0.323.865.1989.
8. Shafice A., Chen T. S., Byron S. et al. Enzymatic synthesis and immuno-suppressive activity of novel desmethylated immunomycins (ascomycins). J Antibiotics 1993; 46: 1397-1405.
9. Vezina C., Kudelski A., Sehgal S. N. Rapamycin (AY22.989), a new anti-fungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. Ibid, 1975; 28: 721-726.
10. Hashemolhosseini S., Nagamine Y., Morley S. J. et al. Rapamycin inhibition of G-1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998; D2: 273: 23: 14424-14429.
11. Berset C., Trachsel H., Altmann M. The TOR (target of rapamycin) signal transduction pathway regulated the stability of translation initiation factor eIF4G in the yeast Sacharomyces cerevisiae. Proc Natl Acad Sci 1998; 95: 8: 4264-4269.
12. Sanglier J. J., Quesniaux V., Fehr T. et al. Sanglifehrins A,B,C and D. Novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. 1. Taxonomy, fermentation, isolation and biological activity. J Antibiotics 1999; 52: 5: 466-473.
13. Sweeney M. J., Hoffman D. H., Esterman M. A. Metabolism and biochemistry of mycophenolic acid. Cancer Res 1972; 32: 1803-1809.
14. Allison A. C., Eugei E. M. Micophenolate Mofetil (RS-61443) mode of action and effects on graft rejection. Immunosuppressive drugs, developments in anti-rejection therapy. A. W. Thompson, T. F. Starzl. Edward Arnold, eds. New York, 1994; 141-159.
15. Strom T. T cells are doing to accept transplants. Abstracts of 1 joint annuel meeting of the American Society of transplant surgeons. May 12-17, Chicago, 2000.
16. Kluepfel D., Vezina C. et al. Myriocin, a new antifungal antibiotic from Myriococcum albomyces. J Antibiotics 1972; 25: 109-115.
17. Fujita T., Okumoto T. et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. Ibid 1994; 47: 208-215.
18. Sasaki S., Fujita T. et al. Fungal metabolites. Part 14. Novel potent immunosuppressant, mycestericins, produced by Mycelia sterilia. Ibid 1994; 47: 420-433.
19. Weiss B., Stoffel W. Human and murine serine-palmitoil-CoA transferase - cloning, expression and characterization of the key enzyme in sphingolipid synthesis. Eur J Biochem 1997; 249: 239-247.
20. Pushkareva M. Y., Khan W. A. et al. Sphingosine activation of protein kinases in Jurkat T cells. J Biol Chem 1992; 267: 15246-15251.
21. Lee M., Hia T. et al. Sphingosine-1 -phosphate as a ligand for the G protein receptor EDG-1. Science 1998; 279: 1552-1554.
22. Chen J. K., Lane W. S., Schreiber S. L. The identification of myriocin-binding proteins. Chemistry Biology 1999; 6: 221-235.
23. Fujita T., Hirose R. et al. 2-Substituted 2-aminoethanol: minimum essential structure for immunosuppressive activity of ISP-1 (miriocin). Bioorg Med Chem 1995; 5: 1857-1860.
24. Yanagava Y., Sugahara K. et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts not cytokine production. J Immunol 1998; 160: 5493-5499.
25. Laaysch H., Kellner M., Wolf G. et al. Oligomycin F, a new immunosuppressive homologue of oligomycin A. J Antibiotics 1993; 46: 1334-1338.
26. Cho J. H., Balasubramanyam M. et al. Oligomycin inhibits store-operated channels by a mechanism independent of its effects on mitochondrial ATP. Biochem J 1997; 324: 971-980.
27. Salomon A. R., Voehringer D. W. et al. Understanding and exploiting the mechanism basis for selectivity polycetide inhibitors of F0-F1-ATFase. Pharmacology 2000; 97: 14766-14771.
28. Lauft U., Liao J. K. Direct vascular effects of HMG-CoA reductase inhibitors. Trends-Cardiovasc-Med. 2000; 10: 143-148.
29. Takemolo M., Liao J. K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Aterioscler Thromb Vasc Biol 2001; 21: 1712-1719.
30. Weis M., Heeschen C. et al. Stalins have biphasic effects on angiogenesis. Circulation. 2002; 105: 739-745.
31. Kiener P. A., Davis P. M. et al. Stimulation of inflammatory responses in vivo and in vitro by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol 2001; 1: 105-118.
32. Ridker P. M. High-sensitivy C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1818.
33. Takeuchi T., Iinuma H., Kunimoto S. et al. A new antitumor antibiotic Spergualin. Isolation and antitumor activity. J Antibiotics 1981; 34: 1619-1621.
34. Masuda T., Mizutani S., Iinuma H. et al. Immunosuppressive activity of 15-deoxyspergualin and its effect on skin allograft in rats. Ibid; 1987; 40: 1612-1618.
35. Nemoto H., Hayshi M., Abe F. Immunosuppressive activities of of 15-deoxyspergualin in animals. Ibid; 1987; 40: 561-562.
36. Nemoto K., Hayashi M. et al. Deoxyspergualin in lethal murine graft versus host diesease. Transplantation 1991; 51: 712-715.
37. Nemoto K., Hayashi M. et al. Biological activities of deoxyspergualin in autoimmune diesease mice. J. Antibiotics 1988; 40: 1448-1451.
38. Makino M., Fujiwara M., Watanabe H. et al. Immunosuppressive activities of deoxyspergualin. II. The effect on the antibody responses. lmmunopharmacology 1987; 14: 115-122.
39. Nosaka C., Kunimoto S., Atsumi S., Takeuchi T. Inhibition of nitric oxide synthease induction by 15-deoxyspergualin in a cultured macrophage cell line, J744A. 1 with IFN-gamma and LPS. J Antibiotics 1999; 52: 297-304.
40. Ordan H., Fukuda Y. et al. Simultaneous evaluation of nitric oxide synthesis and oxygenation in rat liver allograft rejection using near-infrared spectroscopy. Transplantation. 1996; 60: 530-535.
41. Takahashi K., Oka K., Tanabe K. Effect of a novel immunosuppressive Deoxyspergualin on rejection in kidney transplantations. Transplant Proc 1990; 22: 1606-1612.
42. Stepkowski S. M. Molecular targets for existing and novel immunosuppressive drugs. Expert Reviews in Molecular Medicine 2000; Cambridge University Press, http://www.ermm.cbcu.cam.ac.uk/00001769a.pdf.